Table of Contents
ISRN Endocrinology
Volume 2013 (2013), Article ID 104850, 9 pages
http://dx.doi.org/10.1155/2013/104850
Research Article

Aryl Hydrocarbon Receptor Ligands Inhibit IGF-II and Adipokine Stimulated Breast Cancer Cell Proliferation

1Department of Pharmacology, Physiology and Toxicology, Joan C. Edwards School of Medicine, Marshall University, 1 John Marshall Drive, Huntington, WV 25755, USA
2Department of Science and Mathematics, Glenville State College, WV 26351, USA

Received 16 July 2013; Accepted 13 August 2013

Academic Editors: C. M. Perks, H.-Q. Qu, and J. A. Rillema

Copyright © 2013 Travis B. Salisbury et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. E. Calle, “Obesity and cancer,” British Medical Journal, vol. 335, no. 7630, pp. 1107–1108, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. E. E. Calle and R. Kaaks, “Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms,” Nature Reviews Cancer, vol. 4, no. 8, pp. 579–591, 2004. View at Google Scholar · View at Scopus
  3. M. J. Khandekar, P. Cohen, and B. M. Spiegelman, “Molecular mechanisms of cancer development in obesity,” Nature Reviews Cancer, vol. 11, no. 12, pp. 886–895, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Iyengar, T. P. Combs, S. J. Shah et al., “Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization,” Oncogene, vol. 22, no. 41, pp. 6408–6423, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Iyengar, V. Espina, T. W. Williams et al., “Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment,” Journal of Clinical Investigation, vol. 115, no. 5, pp. 1163–1176, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. N. K. Saxena, P. M. Vertino, F. A. Anania, and D. Sharma, “Leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3,” Journal of Biological Chemistry, vol. 282, no. 18, pp. 13316–13325, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. X. Hu, S. C. Juneja, N. J. Maihle, and M. P. Cleary, “Leptin: a growth factor in normal and malignant breast cells and for normal mammary gland development,” Journal of the National Cancer Institute, vol. 94, no. 22, pp. 1704–1711, 2002. View at Google Scholar · View at Scopus
  8. V. D'Esposito, F. Passaretti, A. Hammarstedt et al., “Adipocyte-released insulin-like growth factor-1 is regulated by glucose and fatty acids and controls breast cancer cell growth in vitro,” Diabetologia, vol. 55, no. 10, pp. 2811–2822, 2012. View at Google Scholar
  9. L. Vona-Davis and D. P. Rose, “Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression,” Endocrine-Related Cancer, vol. 14, no. 2, pp. 189–206, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Bahrenberg, I. Behrmann, A. Barthel et al., “Identification of the critical sequence elements in the cytoplasmic domain of leptin receptor isoforms required for Janus kinase/signal transducer and activator of transcription activation by receptor heterodimers,” Molecular Endocrinology, vol. 16, no. 4, pp. 859–872, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. D. H. Cohen and D. LeRoith, “Obesity, type 2 diabetes, and cancer: the insulin and IGF connection,” Endocrine-Related Cancer, vol. 19, no. 5, pp. F27–F45, 2012. View at Google Scholar
  12. E. J. Gallagher and D. LeRoith, “Minireview: IGF, insulin, and cancer,” Endocrinology, vol. 152, no. 7, pp. 2546–2551, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. E. A. Musgrove, C. E. Caldon, J. Barraclough, A. Stone, and R. L. Sutherland, “Cyclin D as a therapeutic target in cancer,” Nature Reviews Cancer, vol. 11, no. 8, pp. 558–572, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Safe, C. Qin, and A. McDougal, “Development of selective aryl hydrocarbon receptor modulators for treatment of breast cancer,” Expert Opinion on Investigational Drugs, vol. 8, no. 9, pp. 1385–1396, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Zhang, P. Lei, X. Liu et al., “The aryl hydrocarbon receptor as a target for estrogen receptor-negative breast cancer chemotherapy,” Endocrine-Related Cancer, vol. 16, no. 3, pp. 835–844, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. J. D. Mezrich, L. P. Nguyen, G. Kennedy et al., “SU5416, a VEGF receptor inhibitor and ligand of the AHR, represents a new alternative for immunomodulation,” PloS ONE, vol. 7, no. 9, Article ID e44547, 2012. View at Google Scholar
  17. M. S. Denison, A. A. Soshilov, G. He, D. E. Degroot, and B. Zhao, “Exactly the same but different: promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon (dioxin) receptor,” Toxicological Sciences, vol. 124, no. 1, Article ID kfr218, pp. 1–22, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. J. A. Sparano, M. Wang, F. Zhao et al. et al., “Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer,” Cancer, vol. 118, no. 23, pp. 5937–5946, 2012. View at Google Scholar
  19. D. T. Worster, T. Schmelzle, N. L. Solimini et al., “Akt and ERK control the proliferative response of mammary epithelial cells to the growth factors IGF-1 and EGF through the cell cycle inhibitor p57Kip2,” Science Signaling, vol. 5, no. 214, article ra19, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. R. J. Lee, C. Albanese, M. Fu et al., “Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway,” Molecular and Cellular Biology, vol. 20, no. 2, pp. 672–683, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Toualbi-Abed, F. Daniel, M. C. Güller et al., “Jun D cooperates with p65 to activate the proximal κB site of the cyclin D1 promoter: role of PI3K/PDK-1,” Carcinogenesis, vol. 29, no. 3, pp. 536–543, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Drabsch, H. Hugo, R. Zhang et al., “Mechanism of and requirement for estrogen-regulated MYB expression in estrogen-receptor-positive breast cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 34, pp. 13762–13767, 2007. View at Publisher · View at Google Scholar · View at Scopus